by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as...
by MM360 Staff | May 31, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by MM360 Staff | May 30, 2025 | Uncategorized
Source: ASCO Daily News In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of...
by MM360 Staff | May 30, 2025 | Myeloma News
Source: Pharmacy Times articles Building on positive low-density lipoprotein cholesterol (LDL-C)-lowering seen in patients with atherosclerotic cardiovascular disease, inclisiran was found to induce meaningful and sustained LDL-C reductions following recent acute...
by MM360 Staff | May 30, 2025 | Uncategorized
Source: CureToday articles New treatment combinations are transforming genitourinary cancer care, improving survival and quality of life while personalizing patient outcomes. Read More
